1. Home
  2. SOS vs BOLT Comparison

SOS vs BOLT Comparison

Compare SOS & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SOS Limited

SOS

SOS Limited

HOLD

Current Price

$1.00

Market Cap

10.7M

Sector

Finance

ML Signal

HOLD

Logo Bolt Biotherapeutics Inc.

BOLT

Bolt Biotherapeutics Inc.

HOLD

Current Price

$4.25

Market Cap

10.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SOS
BOLT
Founded
2004
2015
Country
China
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.7M
10.5M
IPO Year
2005
2021

Fundamental Metrics

Financial Performance
Metric
SOS
BOLT
Price
$1.00
$4.25
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$34.00
AVG Volume (30 Days)
181.7K
12.8K
Earning Date
05-14-2026
03-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$7,695,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$56.43
P/E Ratio
N/A
N/A
Revenue Growth
N/A
0.07
52 Week Low
$0.92
$0.26
52 Week High
$8.92
$7.35

Technical Indicators

Market Signals
Indicator
SOS
BOLT
Relative Strength Index (RSI) 34.88 43.17
Support Level N/A $3.91
Resistance Level $1.92 $5.01
Average True Range (ATR) 0.21 0.34
MACD -0.03 0.05
Stochastic Oscillator 6.82 40.27

Price Performance

Historical Comparison
SOS
BOLT

About SOS SOS Limited

SOS Ltd is a multifaceted company that leverages the power of data to provide marketing solutions, while also participating in the burgeoning fields of blockchain and cryptocurrency operations, as well as commodity trading. Its product offerings are diversified across four main areas: commodity trading, insurance marketing, cryptocurrency mining, and other services. The company has three reporting segments: Commodity trading, Cryptocurrency mining, and Others. Key revenue is generated from Commodity trading.

About BOLT Bolt Biotherapeutics Inc.

Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.

Share on Social Networks: